IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung ...
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 24, 2026-- Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI ® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the …